XEN402 is currently in clinical development for a variety of painful disorders.
Teva will pay Xenon an upfront fee of $41 million, as agreed in this pharma partnering deal.
Also stated in this pharma partnering agreement is a clause that requires Teva to pay development, regulatory, and sales-based milestones totaling up to $335M in addition to the upfront fee.
Xenon is entitled to royalties payable on sales and an option to participate in commercialization in the U.S.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Teva
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity